MLICM
VIGL

Metropolitan Life Insurance Company (MetLife)’s Vigil Neuroscience VIGL Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio VIGL Stock Details VIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-944
Closed -$8.87K – 2449
2023
Q2 		$8.87K Buy
+944
New +$8.93K ﹤0.01% 2359

Other funds holding VIGL

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
NV
Northpond Ventures Bethesda, Maryland $43.7M AUM 27.27% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s VIGL Position: Q3 2023 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Vigil Neuroscience (VIGL) in Q3 2023, closing a stake of 944 shares — an estimated $8.87K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in VIGL in Q2 2023 and held it in 1 quarter. The position peaked at $8.87K in Q2 2023. 45 funds tracked by Wall St. Rank hold VIGL as of Q3 2023.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Vigil Neuroscience position as of Q3 2023 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 944 Vigil Neuroscience shares in Q3 2023, an estimated $8.87K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Vigil Neuroscience in Q2 2023 and held it in 1 quarter.
  • Metropolitan Life Insurance Company (MetLife)'s Vigil Neuroscience position peaked at $8.87K in Q2 2023.
  • 45 funds tracked by Wall St. Rank held Vigil Neuroscience as of Q3 2023.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q3 2023, filed 14 Nov 2023.